Dry powder aerosol containing muco-inert particles for excipient enhanced growth pulmonary drug delivery.

Administration, Inhalation Cystic Fibrosis / drug therapy Drug Delivery Systems Dry Powder Inhalers / methods Excipients / chemistry Humans Lung / drug effects Lung Diseases / drug therapy Mucus / drug effects Nanoparticles / chemistry Polyethylene Glycols / chemistry Polystyrenes / chemistry
CF sputum Dry powder inhaler Mucus penetration Multiple particle tracking Spray drying

Journal

Nanomedicine : nanotechnology, biology, and medicine
ISSN: 1549-9642
Titre abrégé: Nanomedicine
Pays: United States
ID NLM: 101233142

Informations de publication

Date de publication:
10 2020
Historique:
received: 27 05 2020
revised: 21 06 2020
accepted: 26 06 2020
pubmed: 6 7 2020
medline: 8 7 2021
entrez: 6 7 2020
Statut: ppublish

Résumé

Tenacious sputum poses a critical diffusion barrier for aerosol antibiotics used to treat cystic fibrosis (CF) lung infection. We conducted a proof-of-concept study using dense poly(ethylene glycol) coated polystyrene nanoparticles (PS-PEG NPs) as model muco-inert particles (MIPs) formulated as a powder using an excipient enhanced growth (EEG) strategy, aiming to minimize extrathoracic airway loss, maximize deposition in the airway and further overcome the sputum barrier in the CF lungs. The EEG aerosol formulation containing PS-PEG MIPs was prepared by spray drying and produced discrete spherical particles with geometric diameter of approximately 2 μm; and >80% of the powder dose was delivered from a new small-animal dry powder inhaler (DPI). The MIPs released from the EEG aerosol had human airway mucus and CF sputum diffusion properties comparable to the suspension formulation. These properties make this formulation a promising pulmonary drug delivery system for CF lung infections.

Identifiants

DOI: 10.1016/j.nano.2020.102262 PMID: 32623017 PMC: PMC7508849
pubmed: 32623017
pii: S1549-9634(20)30116-7
doi: 10.1016/j.nano.2020.102262
pmc: PMC7508849
mid: NIHMS1609094
pii:
doi:

Substances chimiques

Excipients 0
Polystyrenes 0
Polyethylene Glycols 3WJQ0SDW1A

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

102262

Subventions

Organisme : NEI NIH HHS
ID : R01 EY027827
Pays : United States
Organisme : FDA HHS
ID : HHSF223201810114C
Pays : United States
Organisme : NIDA NIH HHS
ID : UG3 DA048768
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD087339
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146160
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

FEMS Microbiol Lett. 2009 Nov;300(2):153-64
pubmed: 19674113
Adv Drug Deliv Rev. 2009 Feb 27;61(2):158-71
pubmed: 19133304
Chest. 1999 Apr;115(4):1120-6
pubmed: 10208218
JCI Insight. 2016 Nov 3;1(18):e88198
pubmed: 27812540
Adv Mater. 2012 Jul 24;24(28):3887-94
pubmed: 22988559
Nanomedicine. 2015 Feb;11(2):401-5
pubmed: 25461289
N Engl J Med. 2005 May 12;352(19):1992-2001
pubmed: 15888700
Angew Chem Int Ed Engl. 2008;47(50):9726-9
pubmed: 18979480
J Pharm Pharmacol. 2012 Sep;64(9):1254-63
pubmed: 22881438
Nanomedicine (Lond). 2011 Feb;6(2):365-75
pubmed: 21385138
J Clin Pharmacol. 2007 Oct;47(10):1335-41
pubmed: 17625157
Chest. 2009 Feb;135(2):505-512
pubmed: 19201713
Adv Drug Deliv Rev. 2009 Feb 27;61(2):75-85
pubmed: 19135107
J Control Release. 2013 Sep 10;170(2):279-86
pubmed: 23751567
Pharm Res. 2020 May 21;37(6):101
pubmed: 32440940
Aerosol Sci Technol. 2011 Jan 1;45(7):884-899
pubmed: 21804683
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8720-5
pubmed: 26124127
ACS Nano. 2015 Sep 22;9(9):9217-27
pubmed: 26301576
Adv Drug Deliv Rev. 2015 May;85:83-99
pubmed: 25451137
J Control Release. 2014 Mar 28;178:8-17
pubmed: 24440664
Am J Respir Crit Care Med. 2000 Nov;162(5):1905-11
pubmed: 11069833
N Engl J Med. 2010 Dec 2;363(23):2233-47
pubmed: 21121836
Med Devices (Auckl). 2011;4:179-88
pubmed: 22915944
Mol Ther. 2014 Aug;22(8):1484-1493
pubmed: 24869933
Paediatr Respir Rev. 2007 Mar;8(1):4-7
pubmed: 17419972
Biomaterials. 2009 May;30(13):2591-7
pubmed: 19176245
Mol Med Today. 1999 Aug;5(8):351-8
pubmed: 10431168
J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):248-65
pubmed: 23286828
Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69
pubmed: 17761616
Sci Adv. 2017 Apr 05;3(4):e1601556
pubmed: 28435870
Adv Drug Deliv Rev. 2015 Aug 30;91:70-91
pubmed: 25858664
Expert Opin Drug Deliv. 2015 Jun;12(6):947-62
pubmed: 25388926
Mol Ther. 2016 Dec;24(12):2043-2053
pubmed: 27646604
J Cyst Fibros. 2012 Dec;11(6):461-79
pubmed: 23137712
Sci Transl Med. 2012 Aug 29;4(149):149ra119
pubmed: 22932224
Int J Pharm. 2013 Feb 25;443(1-2):137-45
pubmed: 23313343
Biomaterials. 2013 Apr;34(13):3439-46
pubmed: 23384790
Eur J Pharm Sci. 2013 Jun 14;49(3):390-9
pubmed: 23608613
Respir Med. 2002 May;96(5):293-304
pubmed: 12113378
J Control Release. 2018 Sep 10;285:35-45
pubmed: 30004000
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916

Auteurs

Guihong Chai (G)

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.

Amr Hassan (A)

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.

Tuo Meng (T)

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.

Lihua Lou (L)

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.

Jonathan Ma (J)

Department of Pediatrics, Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, VA, USA.

Russell Simmers (R)

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA; Department of Physics, College of Humanities & Sciences, Virginia Commonwealth University, Richmond, VA, USA.

Lei Zhou (L)

Department of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.

Bruce K Rubin (BK)

Department of Pediatrics, Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, VA, USA.

Qi Tony Zhou (QT)

Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN, USA.

P Worth Longest (PW)

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA; Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, USA.

Michael Hindle (M)

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.

Qingguo Xu (Q)

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA; Department of Ophthalmology, Massey Cancer Center, Center for Pharmaceutical Engineering, and Institute for Structural Biology, Drug Discovery & Development (ISB3D), Virginia Commonwealth University, Richmond, VA, USA. Electronic address: qxu@vcu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par inhalation › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies néonatales › Mucoviscidose › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Équipement et fournitures › Nébuliseurs et vaporisateurs › Inhalateurs à poudre sèche › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Excipients pharmaceutiques › Excipients › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Appareil respiratoire › Poumon › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Maladies pulmonaires › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Liquides et sécrétions biologiques › Sécrétions corporelles › Mucus › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyéthylène glycols › Dry powder aerosol containing muco-inert...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Matières plastiques › Polystyrènes › Dry powder aerosol containing muco-inert...